Everolimus: a challenging drug in the treatment of multifocal inoperable cardiac rhabdomyoma.
Primary cardiac tumors are rare in childhood. The most common of these are rhabdomyomas. Considering that rhabdomyomas often show spontaneous regression, close follow-up may be sufficient in hemodynamically stable cases. However, hemodynamically significant cardiac rhabdomyomas confer a risk of morbidity and mortality. Herein, we report a newborn infant with multifocal cardiac rhabdomyomas treated with everolimus. The optimal dose of the drug was 0.25 mg 2 times per day, 2 days per week. Patients with inoperable cardiac rhabdomyomas and with symptoms may be candidates for everolimus treatment.
Department of Pediatric Hematology/Oncology, Ankara Children’s Hematology Oncology Education and Research Hospital, Ankara, Turkey. hdemir@hacettepe.edu.tr
Haci Ahmet
HA
Demir
Filiz
F
Ekici
Arzu
A
Yazal Erdem
Suna
S
Emir
Bahattin
B
Tunç
D000068338:Everolimus; D006338:Heart Neoplasms / Q000151:congenital / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D012207:Rhabdomyoma / Q000151:congenital / Q000175:diagnosis / Q000188:drug therapy*; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use
D047428:Protein Kinase Inhibitors; D000068338:Everolimus; D020123:Sirolimus